Neurally Adjusted Ventilatory Assist (NAVA) or Pressure Support Ventilation (PSV) during spontaneous breathing trials in critically ill patients: a crossover trial

Table 1 Patient’s demographics and ventilator settings at baseline

ID	SAPS 3	Cause of Resp. Failure	Duration of MV (days)	PSV (cmH₂O)	PEEP (cmH₂O)	Cycling off	FIO₂
1	67	COPD exacerbation	5	10	5	30%	0.3
2	71	COPD exacerbation	2	17	7	35%	0.4
3	70	COPD exacerbation	7	12	6	40%	0.35
4	84	Trauma	12	12	5	35%	0.3
5	95	Sepsis	6	7	8	20%	0.35
6	97	Cardiac arrest	3	10	8	30%	0.3
7	55	Coma	9	9	8	30%	0.4
8	65	Metabolic acidosis	8	8	6	40%	0.35
9	71	Pneumonia	3	6	6	30%	0.3
10	39	Pneumonia	5	7	6	25%	0.25
11	76	Pneumonia	7	8	8	30%	0.35
12	48	Drowning	7	10	10	15%	0.3
13	76	Pleural effusion	7	10	6	30%	0.3
14	57	Cardiac failure	10	10	8	30%	0.35
15	50	COPD exacerbation	4	8	5	60%	0.35
16	65	Pneumonia	3	6	8	25%	0.35
17	69	Pneumonia	6	10	5	25%	0.3
18	44	COPD exacerbation	11	12	6	40%	0.5
19	58	COPD exacerbation	5	15	8	50%	0.5
20	32	COPD exacerbation	4	10	5	30%	0.35

SAPS 3 Simplified acute physiology score 3, Resp. Failure respiratory failure, MV Mechanical ventilation, PSV Pressure Support Ventilation level on the day of the study, PEEP positive end-expiratory pressure on the day of the study, FIO ₂ inspired fraction of oxygen, COPD Chronic Obstructive Pulmonary Disease. Duration of mechanical ventilation is shown in days before inclusion in the trial

ISSN: 1471-2466